TNGX
NASDAQTango Therapeutics Inc.
Price$24.76-0.57 (-2.25%)
01:30 PM07:45 PM
News · 26 weeks75+1300%
2026-03-012026-08-23
Mix3990d
- SEC Filings15(38%)
- Insider9(23%)
- Other8(21%)
- Analyst3(8%)
- Offering2(5%)
- Leadership2(5%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 424B5 filed by Tango Therapeutics Inc.424B5 - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRNeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight FloatDENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near its 52-week low, a relatively small trading float, more than 500,000 shares reported short, three Wall Street Buy ratings and a long-awaited brain-cancer data readout. The question is whether the clinical data can justify the attention. NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The compa
- SECTango Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 10-Q filed by Tango Therapeutics Inc.10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsCompany continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESMO Congress Key appointments further position Company for late-stage development and commercialization: Robert Azelby, Chairman of the Board of Directors and Fatma Ocak, Chief Commercialization Officer Cash position of $1.0 billion as of June 30, 2026 BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX) (Tango or the Company), a clinical-stage biotechnology company commit
- SECAmendment: Tango Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K/A - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Announces Executive Chair TransitionBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits. "I am proud with what we have achieved at Tango and am confident that the Company is extremely well positioned to build on those achievements," Dr. Weber said. "The Company is profoundly grateful to Dr. Weber for all that she has brought to it: vision, leadership, passion for Tango and its employees and commitment
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- INSIDERPresident, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $735,517 worth of shares (27,000 units at $27.24) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- ANALYSTAnalyst initiated coverage on Tango Therapeutics with a new price targetAnalyst initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $46.00
- INSIDERPresident, R&D Crystal Adam sold $798,908 worth of shares (27,000 units at $29.59) as part of a pre-agreed trading plan and exercised 27,000 shares at a strike of $5.20 (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- ANALYSTTango Therapeutics upgraded by Jefferies with a new price targetJefferies upgraded Tango Therapeutics from Hold to Buy and set a new price target of $60.00
- INSIDERDirector Azelby Robert was granted 5,740 shares (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERSEC Form 3 filed by new insider Azelby Robert3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Appoints Robert Azelby to Board of DirectorsBOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with
- SECSEC Form 144 filed by Tango Therapeutics Inc.144 - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 424B5 filed by Tango Therapeutics Inc.424B5 - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 144 filed by Tango Therapeutics Inc.144 - Tango Therapeutics, Inc. (0001819133) (Subject)
TNGX FAQ
7 questionsWhat does Tango Therapeutics Inc. do?
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and...Where does TNGX stock trade?
Tango Therapeutics Inc. (TNGX) is listed on NASDAQ.What sector and industry is TNGX in?
Tango Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tango Therapeutics Inc. go public?
Tango Therapeutics Inc. (TNGX) completed its IPO in 2020.What are analysts saying about TNGX?
Tango Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $4600.00 price target on 2026-07-15. Recent price targets range from $1900.00 to $4600.00.What companies are similar to TNGX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TNGX side-by-side with any of them on Quantisnow.How can I track TNGX on Quantisnow?
Quantisnow aggregates Tango Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNGX to receive live email and push alerts on every new disclosure.